Drug Discovery & Pharmaceuticals

RSS

PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), and RxCelerate, a leading international out-sourced drug discovery and development service provider, today announced the successful completion of a collaboration to assess small molecules identified from an initial cheminformatics drug screen in a bespoke cell-based assay developed by RxCelerate on one of PlaqueTec’s targets discovered in pilot studies.

18 Sep 2024

Pushing the limits — Pharma characterization with light scattering

Bettersize's upcoming webinar will delve into particle size and zeta potential, showcasing their importance in pharmaceutical development and product quality.

From Bettersize Instruments Ltd. 18 Sep 2024

Early specificity testing crucial for antibody drug safety

Integral Molecular, a leader in antibody discovery and characterization, has published new research in the journal mAbs, revealing that as many as one-third of antibody-based drugs exhibit nonspecific binding to unintended targets.

18 Sep 2024

New insights into the mechanisms of efavirenz-induced neurotoxicity

Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients' quality of life over time. It causes neuropsychiatric disorders and neurocognitive impairment in roughly 50 percent of patients. The drug is associated with abnormal lipid levels in blood plasma, but the molecular mechanisms responsible for negative clinical observations are unknown.

18 Sep 2024

SwRI collaborates with UTSA to develop novel chemical process for synthesizing antibiotics

Southwest Research Institute (SwRI) is collaborating with The University of Texas at San Antonio (UTSA) to explore and develop a novel platform or chemical process for synthesizing antibiotic compounds with a $125,000 grant.

17 Sep 2024

Evolution of vaccine adjuvants from empirical discovery to rational design

Vaccine adjuvants have evolved significantly since their inception, transitioning from empirical discovery to a more structured approach grounded in rational drug design.

13 Sep 2024

ISM2196: A promising AI-developed WRN inhibitor for advanced metastatic cancers

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in-class small molecule WRN inhibitor targeting advanced metastatic microsatellite instability (MSI) cancers guided by synthetic lethality strategy.

13 Sep 2024

Ropirio Therapeutics secures exclusive license for novel lymphatic system activators

The Wyss Institute at Harvard University announced today that Ropirio Therapeutics, Inc. (Ropirio) has secured a worldwide, exclusive license from Harvard's Office of Technology Development (OTD) and Boston University (BU)'s Technology Development office for novel molecules that activate the lymphatic system - a first in the pharma industry.

11 Sep 2024

First crystal structure of alternative DNA shape from the insulin gene revealed

The first crystal structure of an alternative DNA shape from the insulin gene has been revealed by a UCL-led research team.

9 Sep 2024

Insilico Medicine partners with Inimmune to advance immunotherapeutic discovery

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize Chemistry42, Insilico's proprietary generative artificial intelligence (AI) technology to accelerate the discovery and development of next-generation immunotherapeutics.

5 Sep 2024

NSF AIRFoundry to advance RNA technology and nanoparticle design

In a typical foundry, raw materials like steel and copper are melted down and poured into molds to assume new shapes and functions.

3 Sep 2024

New method revolutionizes DNA-encoded chemical libraries

Nowadays, there's lots of buzz about spectacular new medical treatments such as personalised cancer therapy with modified immune cells or antibodies.

2 Sep 2024

New method accelerates drug discovery from years to months

Researchers from the University of Cincinnati College of Medicine and Cincinnati Children's Hospital have found a new method to increase both speed and success rates in drug discovery.

30 Aug 2024

Innovative nickel tool enhances organic chemical reactions for drug creation

The invention of a tool capable of unlocking previously impossible organic chemical reactions has opened new pathways in the pharmaceutical industry to create effective drugs more quickly.

30 Aug 2024

Ingenza announces partnership with Cellugy to investigate the potential of biofabricated cellulose

Industrial biotech specialist Ingenza is delighted to announce that it is collaborating with Cellugy to accelerate the development of its innovative platform for producing biofabricated cellulose. This technology will provide a sustainable alternative to fossil-based petrochemicals in various industrial applications, starting with personal care. The new project will ultimately accelerate the understanding and optimization of bacterial cellulose production.

From Ingenza Ltd 30 Aug 2024

Ishani Malhotra named ‘woman entrepreneur of the year’ by cancer research horizons

Cancer Research Horizons, the innovation arm of Cancer Research UK, announced the winners of its second Innovation & Entrepreneurship Awards at it’s gala dinner on the 20th of March in London.These awards celebrate the UK’s most innovative and enterprising efforts in oncology highlighting those individuals in the industry working hard to translate discoveries into benefits for cancer patients.

From Carcinotech 30 Aug 2024

Carcinotech publishes research on patient-derived 3D-printed tumors as a breakthrough tool for drug development

Advances in tissue engineering and 3D bioprinting have revolutionized the development of physiologically relevant 3D in vitro cancer models, offering a closer representation of the tumor microenvironment (TME) and enabling high-throughput drug screening.

From Carcinotech 30 Aug 2024